From mice to men: Study reveals potential new target for treating acute myeloid leukemia
(AlphaMed Press) A study released in STEM CELLS indicates that blocking transforming growth factor beta 1 (TGFβ1) could improve hematopoiesis in patients with acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 20, 2021 Category: Cancer & Oncology Source Type: news

IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. These data ...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Combination therapy achieves high rates of response for patients with ALL
(University of Texas M. D. Anderson Cancer Center) A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center. The study may support a regimen to produce complete remission with front-line therapy, without the increased risks associated with systemic chemotherapy or a stem cell transplant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2021 Category: Cancer & Oncology Source Type: news

UAMS Researcher Gets $1.27M for Cancer Study
A researcher with the Winthrop P. Rockefeller Cancer Institute gets a five-year, $1.27 million grant to work toward developing two treatment options for acute myeloid leukemia patients. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - May 11, 2021 Category: American Health Source Type: news

Philip Schofield hails 'big step forward' cancer treatment that's saving lives
A GAME-CHANGING treatment for acute lymphoblastic leukaemia - a rare cancer of the blood cells - has been discovered. Philip Schofield remarked on the findings on ITV's This Morning on Monday. (Source: Daily Express - Health)
Source: Daily Express - Health - May 4, 2021 Category: Consumer Health News Source Type: news

Using personalized medicine to avoid resistance to leukemia treatment
T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20. The standard treatment for T-ALL involves heavy chemotherapy procedures, which result in favorable outcomes with an overall survival of 75% after 5 years. (Source: World Pharma News)
Source: World Pharma News - May 4, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Study finds potential therapeutic target for pediatric acute myeloid leukemia
(Nemours) Researchers have identified a gene expressed in children with acute myeloid leukemia (AML) that could serve as a new immunotherapy treatment target, according to a new study published today in Blood Advances, a journal of the American Society of Hematology. The study, co-authored by researchers with Nemours Children's Health System, outlines the process and potential path for new immunotherapy drugs that improve survival and reduce treatment-related toxicity in children with AML. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 4, 2021 Category: Cancer & Oncology Source Type: news

Using personalized medicine to avoid resistance to leukemia treatment
(University of Copenhagen - The Faculty of Health and Medical Sciences) T-cell acute lymphoblastic leukemia is an aggressive cancer type that mostly affects children. The standard treatment is chemotherapy, but about one in four patients do not respond or develop resistance to this. Now, researchers from the University of Copenhagen have found a combination treatment that could benefit these patients and increase the survival rate. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 4, 2021 Category: Cancer & Oncology Source Type: news

Healthcare use and costs for childhood acute lymphoblastic leukaemia differ by treatment protocol in Ontario, Canada
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2021 Category: Drugs & Pharmacology Source Type: news

New genetic target for blood cancer treatment
(Wellcome Trust Sanger Institute) Researchers have identified a vulnerability in some cases of acute myeloid leukaemia that could be harnessed for targeted treatment of these poor-prognosis cancers (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 30, 2021 Category: Cancer & Oncology Source Type: news

Steroids Unrelated to Psychological Reactions in Pediatric ALL
MONDAY, April 26, 2021 -- For children with acute lymphoblastic leukemia (ALL), the type/dose of steroid seems not to be related to adverse psychological reactions (APRs) but may be associated with sleep problems, according to a review published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 26, 2021 Category: Pharmaceuticals Source Type: news

Scientists develop new class of cancer drug with potential to treat leukaemia
(University of Cambridge) Scientists have made a promising step towards developing a new drug for treating acute myeloid leukaemia, a rare blood disorder. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 26, 2021 Category: Cancer & Oncology Source Type: news

EU Panel Likes Azacitidine for AML Maintenance EU Panel Likes Azacitidine for AML Maintenance
The EMA ' s Committee for Medicinal Products for Human Use adopted a positive opinion of the drug for use as maintenance therapy in patients with acute myeloid leukemia.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 24, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Roche announces positive CHMP opinion for Venclyxto-based combinations in certain patients with acute myeloid leukaemia
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Bas ed on this positive CHMP recommendation, a final decision regarding the approval of Venclyxto in certain patients with untreated AML is expected from the European Commission in the near future.“Today’s recommendation...
Source: Roche Investor Update - April 23, 2021 Category: Pharmaceuticals Source Type: news

Children With Down Syndrome at Higher Risk for Leukemia
Risk particularly high for acute myeloid leukemia before age 5 years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 20, 2021 Category: Cancer & Oncology Tags: Family Medicine, Oncology, Pathology, Pediatrics, Radiology, Journal, Source Type: news